HYSTEROSCOPIC STERILISATION USING AN INTRATUBALAL DEVICE

P. Rocha, C. Rodrigues, V. Loureiro, T.P. Correia

9th World Congress on Controversies in Obstetrics, Gynecology & Infertility
Barcelona, March 22-25, 2007
The Essure® permanent birth control system is designed to provide a non-incisional alternative for women seeking sterilisation.

Using a hysteroscopic approach, one micro-insert is placed in the proximal section of each fallopian tube. Tissue in-growth into the micro-insert anchors the device and occludes the fallopian tube (± 3 months).

The micro-insert consists of a stainless steel inner coil, a nickel-titanium, super-elastic outer coil, and polyethylene fibres. When released, the outer coil expands to 1.5 to 2.0 mm to anchor the micro-insert.
INTRODUCTION (II)

**Particular indications**
- Obesity, high risk for general anaesthesia or surgery

**Not indicated**
- Uncertain about definitive contraception
  - Hypersensitivity to nickel
  - No visualization of tubal ostia

**Advantages**
- Rapid procedure, non invasive, outpatient setting, without general anaesthesia or incisions, without hormones, high effective.
OBJECTIVE

To present our initial experience in the use of the intratubal device Essure® for permanent birth control in an outpatient setting.
METHODS (I)

Public hospital with a median of 120 admissions/year to sterilisation.

Retrospective study:
18 women aged 29-45 seeking or proposed to permanent birth control:

↓
12 had medical pathology
(5 of them with high risk for general anaesthesia and/or surgery)
Hysteroscopic sterilisation procedure

- Outpatient setting
- Carried out with paracervical block
- Pre-medications with an anti-inflammatory agent

The procedure details and post procedure follow up were analysed.
HYSTEROSCOPIC STERILISATION USING AN INTRATUBAL DEVICE

METHODS (III)
RESULTS (I)

Procedure details (n=18)

No adverse events were encountered
Good tolerance by the patients

Successful placement was achieved in 17 patients (94%) (one at a second attempt)
One patient with bilateral tubal obstruction
RESULTS (II)

**Follow-up** (3 months / n = 16)
- Bilateral correct device placement (16)
- Bilateral tubal occlusion (9)

Patients satisfaction - 100% after one year.
No pregnancies have been reported to date.
CONCLUSIONS

Despite the small number of cases...

→ The intratubal device Essure® is **safe** and **effective**.

→ The procedure **does not require general anaesthesia** and is made in an **outpatient setting**.

→ It seems to be a **good alternative to laparoscopic tubal sterilisation**.
HYSTEROSCOPIC STERILISATION USING AN INTRATUBAL DEVICE

Thank for your attention!
HYSTEROSCOPIC STERILISATION USING AN INTRATUBAL DEVICE

Bibliography

- Nardin JM et al, Techniques for the interruption of tubal patency for female sterilisation (Cochrane Review), The Cochrane Library, 2006;
- Fernandez, AAGL 2005 Confirmation and development of Essure®’s potential, Surgeon’s Notes, 2005;
- Berral et al, Essure on an outpatient basis, without anaesthesia: Experience with 973 patients in Cordova, Spain, Surgeon’s Notes, 2005;
- Duffy S., Female sterilisation: a cohort controlled comparative study of Essure versus laparoscopic sterilisation, BJOG, Nov 2005;
- Collins G.M., Permanent sterilization for the 21st century using the hysteroscopic approach, Institute for Women’s Health and body, USA, 2004;